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Abstract
The performance of a multiplex real-time PCR for the detection of Blastocystis, Dientamoeba fragilis, Giardia lamblia, Cryptosporidium species
and Entamoeba species in faecal samples was evaluated in an observational prospective study. Paediatric patients (0–18 years) presenting
with gastrointestinal symptoms and suspected of having enteroparasitic disease were included. A questionnaire on gastrointestinal
symptoms and the chosen treatment was completed at the start of the study and after 6 weeks. Of 163 paediatric patients (mean age,
7.8 years), 114 (70%) had a PCR-positive faecal sample. D. fragilis was detected most frequently, in 101 patients, followed by Blastocystis in
49. In faecal samples of 47 patients, more than one protozoan was detected, mainly the combination of D. fragilis and Blastocystis. Reported
gastrointestinal symptoms were abdominal pain (78%), nausea (30%), and altered bowel habits (28%). Eighty-nine of the PCR-positive
patients were treated with antibiotics. A signiﬁcant reduction in abdominal pain was observed both in treated and in untreated patients.
This study demonstrated that multiplex real-time PCR detects a high percentage of intestinal protozoa in paediatric patients with
gastrointestinal symptoms. However, interpretation and determination of the clinical relevance of a positive PCR result in this population
are still difﬁcult.
Keywords: Blastocystis, Dientamoeba fragilis, gastrointestinal symptoms, intestinal protozoa, multiplex real-time PCR, paediatrics, RT-PCR
Original Submission: 17 May 2013; Revised Submission: 29 August 2013; Accepted: 30 August 2013
Editor: E. Bottieau
Article published online: 17 October 2013
Clin Microbiol Infect 2014; 20: 545–550
doi: 10.1111/1469-0691.12386
Corresponding author: B. E. van Ewijk, Department of Paediatrics,
Tergooi Hospitals, Box 10016, 1201 DA Hilversum, The Netherlands
E-mail: bvanewijk@tergooiziekenhuizen.nl
Introduction
Gastrointestinal symptoms, such as abdominal pain, nausea,
acute or chronic diarrhoea, and altered bowel habits, are
frequently seen in paediatric patients. Among several other
causes, intestinal protozoa may be involved. However, the
actual role of protozoal infections in cases with gastrointestinal
symptoms, and therefore the relevance of detection of
intestinal protozoa, is a subject of discussion [1–3].
In The Netherlands, the routine diagnostic procedure for
detection of intestinal protozoa consists of microscopy on
two sodium acetate formalin-preserved stool specimens and
on one unpreserved specimen in a so-called triple faeces test
(TFT) [4]. Although the TFT has shown to be an effective
tool for the detection of intestinal parasites [4], it requires
considerable effort. The patient has to collect three stool
samples on three consecutive days, and the microbiological
laboratory has to examine three samples microscopically. The
complexity of the TFT procedure might be one of the
reasons why only a limited amount of data on the prevalence,
clinical characteristics and treatment outcome of parasitic
gastrointestinal illness in paediatric patients is available.
Real-time PCR has recently been shown to be a sensitive
and speciﬁc diagnostic alternative for the detection of
intestinal protozoa, and some authors recommend its routine
use [5–7]. It is less labour-intensive, and has comparable or
higher sensitivity with only one stool sample instead of three,
making it an attractive alternative to microscopy. However,
no clinical data on the implementation of real-time PCR in
daily paediatric practice are available in these or other
studies.
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This prospective, observational and daily practice study was
undertaken to identify intestinal protozoa in faeces of paedi-
atric patients with gastrointestinal symptoms by use of a
multiplex real-time PCR and to follow up clinical features
6 weeks after inclusion.
Patients and Methods
The study was carried out in the outpatient paediatric
department of a general teaching hospital and in the practices
of ten collaborating general practitioners (GPs). Patients were
included during a 6-month period, from September 2010 to
March 2011. The ethical committee of the hospital approved
the study.
Study design
Paediatric patients (0–18 years) with any presentation of
gastrointestinal symptoms lasting for >2 weeks and/or paedi-
atric patients clinically suspected of having a parasitic gastro-
intestinal illness by the treating paediatrician or GP were
included if their physician decided to perform PCR to detect
intestinal parasites in faeces. Paediatric patients diagnosed with
other common causes of gastrointestinal symptoms were
excluded. This included the suspicion and detection of
gastrointestinal bacteria and viruses, chronic gastrointestinal
morbidity (such as inﬂammatory bowel disease or coeliac
disease), recent use of antibiotics (in the past 6 weeks), and
immunocompromised status.
All paediatric patients and/or their parents completed a
questionnaire about the characteristics of the gastrointestinal
symptoms. The questionnaire consisted of questions on the
presence of abdominal pain, nausea, acute diarrhoea (more
than three loose stools a day, present for <14 days), chronic
diarrhoea (diarrhoea lasting for >14 days), altered bowel
habits (deﬁned as a change in stool pattern other than
diarrhoea), weight loss, vomiting, and anal itching. The severity
of abdominal pain was scored on a validated paediatric visual
analogue scale (VAS), which scores the severity of pain on a
scale from 0 to 10 [8].
After completion of the questionnaire, a multiplex real-time
PCR was performed for Blastocystis, Dientamoeba fragilis,
Giardia lamblia, Cryptosporidium species and Entamoeba species
on a stool sample collected at home (T0). A week after the
ﬁrst visit (T1), the treating physician communicated (by
telephone or at a doctor’s visit) the PCR results. As there is
a lack of evidence concerning both the criteria for starting
treatment and the ideal drug regimen, the choice of whether
or not to treat (and with which type of antibiotic) in the case
of a positive PCR result was left to the treating physician.
Details on treatment were registered. Six weeks after the ﬁrst
visit (T6), all treated and untreated paediatric patients and/or
their parents ﬁlled out the same questionnaire as on T0 in
order to enable follow-up of clinical characteristics, the effect
of treatment, or the natural course of the symptoms.
Multiplex real-time PCR for intestinal protozoa
For the multiplex real-time PCR c. 200 mg of unpreserved
faeces was dissolved in 400 lL of lysis buffer (DXL; Qiagen,
Hilden, Germany), and, after storage at 20°C overnight, was
used for DNA extraction. Prior to automated DNA extrac-
tion, phocin herpesvirus (PhHV-1) was added to the faecal
sample to serve as an internal control for determining the
efﬁciency of the PCR and detecting inhibition in the sample [9].
Detection of the ﬁve protozoa was performed in two separate
PCR reactions per DNA sample. In one reaction, a PCR for
G. lamblia and D. fragilis, including PhHV-1, was performed as
described previously [10,11]. In a separate assay, Blastocystis,
Cryptosporidium species, and Entamoeba species, including
PhHV-1, were ampliﬁed [12]. The analytical sensitivity and
speciﬁcity of the PCRs used have been validated at the Leiden
University Medical Centre and Tergooi Hospitals (The Neth-
erlands) [10,11], and conﬁrmed after standardized adjustments
to the analysis parameters in RotorGene software (Qiagen).
Negative extraction and positive DNA controls for each
pathogen were included in all PCR runs.
Statistical analysis
Dichotomous and categorical variables were compared by use
of the v2-test, and continuous data were analysed with
non-parametric tests as applicable. All statistical analyses were
performed with SPSS version 20 (SPSS, Chicago, IL, USA). A
p-value of <0.05 was accepted as statistically signiﬁcant. Data
are expressed as median and range unless stated otherwise.
Results
A total of 171 paediatric patients (61% with gastrointestinal
symptoms lasting for >2 weeks and 39% with clinical suspicion
of parasitic gastrointestinal illness) participated in the study;
eight patients were excluded because they met one of the
exclusion criteria. Real-time PCR was positive in 114 of 163
(70%) of the paediatric patients (Table 1). Because of loss to
TABLE 1. PCR results
PCR-positive PCR-negative
n = 114 (70%) n = 49 (30%)
Ten lost to follow-up Five lost to follow-up
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follow-up (n = 15), analysis of symptoms and follow-up was
performed on data of 104 PCR-positive and 44 PCR-negative
patients (total of 148 patients). The characteristics of these
patients are shown in Table 2. In the PCR-positive group (52
females and 52 males; median age, 7.5 years), the most
commonly reported gastrointestinal complaint was abdominal
pain (78%) (with a mean VAS score of 5.7), followed by nausea
(30%) and altered bowel habits (28%). Most paediatric patients
reported multiple gastrointestinal symptoms. PCR-negative
paediatric patients (25 females and 19 males; mean age,
6.0 years) had comparable gastrointestinal symptoms and VAS
scores (Table 3).
Intestinal protozoal infections
We identiﬁed a single protozoan in 67 (59%) of PCR-positive
paediatric patients, two protozoa in 45 (39%), and three
protozoa in two (2%) (Fig. 1). D. fragilis was detected most
frequently, in 89% (101/114) of PCR-positive patients, followed
by Blastocystis in 43% (49/114). G. lamblia was detected in 9%
(10/114) of PCR-positive patients. We detected no single
infection with Cryptosporidium species and no infection with
Entamoeba species. The most common combination was
D. fragilis and Blastocystis in cases where two protozoa were
detected (Fig. 1).
DNA loads
The median cycle threshold (Ct) values in the real-time PCRs
for the three most prevalent protozoa varied: for D. fragilis,
the median Ct value was 26 (range, 20–39), for Blastocystis it
was 22 (range, 17–35), and for G. lamblia it was 30 (range, 23–
38). No association between DNA loads of a particular
protozoan and gastrointestinal symptoms was found.
Follow-up
Antibiotic treatment was started at T1 in 89 of 104
PCR-positive paediatric patients. In most of these treated
patients (93%), D. fragilis was detected in the multiplex PCR.
Antibiotic treatment consisted of clioquinol 15 mg/kg/day for
10 days in 57 patients (64%) or metronidazole 30 mg/kg/day
for 10 days in 25 patients (28%). In seven patients, treatment
consisted of paromomycine or was unknown. In the antibi-
otic-treated group, abdominal pain was signiﬁcantly reduced in
both frequency and severity according to the VAS score, as
were all other reported gastrointestinal symptoms, except for
altered bowel habits and weight loss (Table 3). In the
untreated group (n = 15), only abdominal pain was signiﬁcantly
diminished after 6 weeks. Finally, in the PCR-negative children
(n = 44), we observed spontaneous, signiﬁcant decreases in
several gastrointestinal symptoms, including the severity of
abdominal pain (VAS score), after 6 weeks (Table 3).
Discussion
Recent studies have shown that PCR is a technically feasible
alternative for detecting intestinal protozoa, with numerous
practical advantages [6,7,10,12–14]. However, the interpreta-
tion and clinical implications of positive real-time PCR results
remain a challenge for the treating physician. We therefore
performed a prospective, observational study in a Dutch
paediatric and GP setting, identifying intestinal protozoa by
PCR in paediatric patients with gastrointestinal symptoms. To
our knowledge, this is the ﬁrst study to prospectively evaluate
such a multiplex real-time PCR from a clinical perspective in
paediatric patients.
The multiplex real-time PCR used in our study was designed
to detect ﬁve commonly foundprotozoa. Almost three-quarters
TABLE 2. Patient demographics
PCR-positive (n = 104) PCR-negative (n = 44)
Age in years (median) 7.5 (0–18) 6 (0–18)
Sex, no. (%)
Female 52 (50) 25 (57)
Male 52 (50) 19 (43)
TABLE 3. Gastrointestinal symptoms at T0 and T6
Gastrointestinal symptoms, no. (%)
Treated patients (n = 89) Untreated patients (n = 15) PCR-negative (n = 44)
T0 T6 p-value T0 T6 T0 T6 p-value
Abdominal pain 69 (78) 29 (33) <0.05 11 (73) 4 (27) <0.05 36 (82) 22 (50) <0.05
Nausea 27 (30) 9 (10) <0.05 4 (27) 2 (13) NS 12 (27) 5 (11) <0.05
Altered bowel habits 24 (27) 17 (19) NS 5 (33) 2 (13) NS 15 (34) 6 (14) <0.05
Chronic diarrhoea 15 (17) 5 (6) <0.05 1 (7) 0 NS 11 (25) 4 (9) <0.05
Weight loss 12 (14) 6 (7) NS 2 (13) 0 NS 8 (18) 2 (5) NS
Anal itching 13 (15) 4 (5) <0.05 3 (20) 1 (7) NS 5 (11) 1 (2) NS
Vomiting 12 (14) 1 (1) <0.05 2 (13) 0 NS 5 (11) 2 (5) NS
Acute diarrhoea 11 (12) 1 (1) <0.05 1 (7) 0 NS 4 (9) 0 NS
Mean VAS score 5.9 4.8 <0.05 5.4 4.5 NS 5.3 4.5 <0.05
NS, not signiﬁcant; VAS, visual analogue scale.
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of the paediatric patients in this study had positive PCR results
for one or more intestinal protozoa, with D. fragilis being
detected in almost all PCR-positive patients. These numbers
are signiﬁcantly higher than those in other studies on intestinal
protozoa, especially on dientamoebiasis [2,5,12,15–18]. These
differences can be related to study set-up and inclusion
criteria, the laboratory techniques used and/or the population
studied in cited studies as compared with our study. We also
found a high number of cases of simultaneous detection of two
or more protozoa. In nearly half of the cases with D. fragilis,
Blastocystis was detected as well. In contrast, Blastocystis as a
single protozoan was seldom seen. Other studies have shown
co-detection in cases of dientamoebiasis, but with signiﬁcantly
lower percentages [5,14]. Gastrointestinal symptoms at
enrolment were not statistically signiﬁcantly different between
paediatric patients with positive or negative PCR results.
Furthermore, no distinct clinical pattern was related to the
presence or the DNA loads of a certain protozoan. These
ﬁndings are in agreement with previous reports [3,15,19]. In
recent decades, the pathogenic potential of D. fragilis has been
increasingly highlighted [15,18,19], whereas this is less clear in
the case of Blastocystis [14,20–23], although, for the latter
species, discrete subtypes might be related to differences in
virulence [21]. Accordingly, most physicians started antipro-
tozoal treatment cases of a positive PCR result for D. fragilis,
but not in cases of single detection of Blastocystis. After
6 weeks, signiﬁcant reductions in almost all gastrointestinal
symptoms were observed in the PCR-positive and treated
patients. However, a signiﬁcant reduction in abdominal pain
was also observed in the PCR-positive, untreated patients and
in the PCR-negative patients. As this study was not pla-
cebo-controlled or randomized, conclusions on the effect of
antibiotic treatment cannot be drawn. However, the sponta-
neous decrease in symptoms in the untreated PCR-positive
patients could possibly be partly explained by single infections
with Blastocystis and its questionable pathogenic nature.
Another explanation could be asymptomatic carriage of
D. fragilis, as has been described for G. lamblia [24,25].
This study has some limitations, mainly owing to the
decision to perform an observational study to describe current
practice prospectively. As data regarding the detection of
intestinal protozoa by PCR and its clinical implications in
paediatric patients are lacking, we chose to perform this study
as a starting point for formulating further research questions
and guiding future study design. The limitations of this study
concern the inclusion criteria: the high percentage of
PCR-positives that we found in our paediatric study population
could be partly the result of selection bias by the treating
physician. Furthermore, a healthy control group is lacking; this
might, for example, have helped to elucidate the role of
asymptomatic carriers. Finally, we did not perform a second
PCR at follow-up, as it is not common routine in our clinical
practice. Analysis of Ct values from positive PCRs among
healthy controls and patient follow-up specimens could also be
helpful in deﬁning the diagnostic value of quantitative PCR
results. These limitations hamper the drawing of conclusions
on the pathogenic role of intestinal protozoa in gastrointestinal
symptoms in paediatric patients and the effect of treatment,
regarding not only symptomatic relief, but also proven
eradication of the protozoa. A randomized placebo-controlled
study is needed to further clarify the relationship between the
presence of intestinal protozoa and gastrointestinal symptoms
in paediatric patients and the effect of treatment.
In conclusion, a multiplex real-time PCR for the detection of
intestinal protozoa is a technically feasible tool in a routine
microbiological laboratory. In paediatric patients with gastro-
intestinal symptoms, high percentages of intestinal protozoa
were detected, but clinical interpretation and the implications
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FIG. 1. Distribution of PCR-detected protozoa in 114 paediatric patients with gastrointestinal symptoms.
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for treatment will need further research to enable the the
development of guidelines for daily clinical practice.
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